Open AccessThe Selective Estrogen Receptor Modulator, Raloxifene, Is Protective Against Renal Ischemia–reperfusion Injury
Author(s) -
Paul T. Hernandez,
C J O'Brien,
Seth J. Concors,
Zhong Lin Wang,
Guanghui Ge,
Wayne W. Hancock,
Matthew Levine
Publication year - 2022
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000004194
Subject(s) - raloxifene , selective estrogen receptor modulator , blood urea nitrogen , medicine , estrogen receptor , estrogen , tamoxifen , creatinine , endocrinology , renal ischemia , kidney , pharmacology , reperfusion injury , ischemia , urology , cancer , breast cancer
There is increasing evidence that estrogen is responsible for improved outcomes in female kidney transplant recipients. Although the exact mechanism is not yet known, estrogen appears to exert its protective effects by ameliorating ischemia-reperfusion injury (IRI). In this study, we have examined whether the beneficial effects of exogenous estrogen in renal IRI are replicated by therapy with any one of several selective estrogen receptor modulators.